Breaking News Instant updates and real-time market news.

ADSK

Autodesk

$176.39

0.99 (0.56%)

, AIXXF

Aixtron

$0.00

(0.00%)

04:55
12/05/19
12/05
04:55
12/05/19
04:55

Berenberg to hold a conference

European Conference 2019 will be held in London, England on December 2-5.

ADSK

Autodesk

$176.39

0.99 (0.56%)

AIXXF

Aixtron

$0.00

(0.00%)

ANSS

Ansys

$252.21

1.95 (0.78%)

AZN

AstraZeneca

$48.21

0.295 (0.62%)

BASFY

BASF

$0.00

(0.00%)

BAYRY

Bayer

$0.00

(0.00%)

DEO

Diageo

$161.78

-0.285 (-0.18%)

E

Eni SpA

$30.22

0.415 (1.39%)

FMS

Fresenius Medical

$36.66

0.365 (1.01%)

GLPG

Galapagos

$205.53

3.65 (1.81%)

GSK

GlaxoSmithKline

$45.07

0.41 (0.92%)

JMPLY

Johnson Matthey

$0.00

(0.00%)

MOR

MorphoSys

$32.08

0.72 (2.30%)

NVO

Novo Nordisk

$57.37

0.835 (1.48%)

NVS

Novartis

$91.56

0.515 (0.57%)

SOLVY

Solvay

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

RYCEY

Rolls-Royce

$0.00

(0.00%)

UL

Unilever

$59.52

0.31 (0.52%)

NVZMY

Novozymes

$0.00

(0.00%)

  • 05

    Dec

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

  • 16

    Dec

  • 21

    Feb

ADSK Autodesk
$176.39

0.99 (0.56%)

12/03/19
ARGS
12/03/19
NO CHANGE
Target $200
ARGS
Buy
Autodesk price target raised to $200 from $184 at Argus
Argus analyst Joseph Bonner raised his price target on Autodesk to $200 and kept his Buy rating after its Q3 earnings beat and narrowed FY20 guidance. The analyst notes that the company continues to expand revenue and margins in spite of the macroeconomic uncertainty. Bonner adds that while the stock is trading at a 28% premium relative to peers on a enterprise value to expected forward revenue basis, that premium is below the 41% premium average over the past two years.
11/27/19
RBCM
11/27/19
NO CHANGE
Target $189
RBCM
Outperform
Autodesk price target raised to $189 from $175 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on Autodesk to $189 and kept his Outperform rating after its Q3 earnings beat and narrowed higher FY20 guidance midpoint. The analyst says the company is making progress around "construction, manufacturing and monetizing its non-paying users", while also citing its maintained annualized recurring revenue guidance that followed "rightsizing for some shift to upfront revenue, product-mix, and FX". Hedberg remains positive on Autodesk given the improving macro backdrop, his higher conviction in the model transition and free cash generation, as well as the company's ability to expand its Annualized Revenue Per Subscription metric.
11/27/19
OPCO
11/27/19
NO CHANGE
Target $200
OPCO
Outperform
Autodesk price target raised to $200 from $175 at Oppenheimer
Oppenheimer analyst Koji Ikeda raised his price target for Autodesk to $200 from $175 saying the company reported "good" Q3 results and increased the full year free cash flow guidance. He believes Autodesk continues to perform well in a "shaky macro environment" and maintains an Outperform rating on the shares.
11/29/19
SBSH
11/29/19
NO CHANGE
SBSH
Buy
Autodesk Q4 guidance should not be viewed negatively, says Citi
Citi analyst Tyler Radke views Autodesk's Q3 results as "solid" as the company's bookings reaccelerated. The guidance, while taking some parsing, is a net positive as fiscal 2020 revenue, billings, and cash flow guidance were largely raised on the Q3 beat, Radke tells investors in a post-earnings research note. And while Q4 annual recurring revenue guidance was below expectations, this shouldn't be viewed negatively as it was impacted by some subscription deals which closed early in Q3 versus Q4 and had to be recognized up front, adds the analyst. He continues to like to shares of Autodesk and keeps a Buy rating on the name.
AIXXF Aixtron
$0.00

(0.00%)

10/28/19
BREN
10/28/19
DOWNGRADE
BREN
Hold
Aixtron downgraded to Hold from Buy at Berenberg
Berenberg analyst Charlotte Friedrichs downgraded Aixtron to Hold from Buy with a price target of 10 euros, down from 12.50 euros. The analyst is cautious on the company's future order intake following last week's guidance cut.
ANSS Ansys
$252.21

1.95 (0.78%)

11/19/19
BNCH
11/19/19
NO CHANGE
Target $265
BNCH
Buy
Ansys price target raised to $265 after investor meetings at Benchmark
Benchmark analyst Mark Schappel said he came away from investor meetings the firm hosted with Ansys management with greater conviction in his core thesis that the engineering simulation arena is a large market driven by favorable secular trends. Following the meetings, Schappel raised his price target on Ansys shares to $265 from $235, though he also expressed "some reservations" about increasing his price target "given the stock's strong run." He reiterates a Buy rating on Ansys shares.
09/16/19
NEED
09/16/19
NO CHANGE
Target $220
NEED
Buy
Ansys price target raised to $220 from $210 at Needham
Needham analyst Richard Valera raised his price target on Ansys to $220 and kept his Buy rating after its "bullish" Investor Day meeting where the management had forecast the company's total addressable market to triple over the next 7-10 years. The analyst cites the growth of new markets for Ansys which include "autonomy, electrification and digital twin", adding that he has incremental bullishness for the company's ability to beat estimates in the near term as well as its long term growth prospects. Valera notes that he would use any near-term weakness as opportunity to get more aggressive on Ansys stock.
10/11/19
WELS
10/11/19
UPGRADE
Target $80
WELS
Outperform
Cadence Design upgraded to Outperform following pullback at Wells Fargo
As previously reported, Wells Fargo analyst Gary Mobley upgraded Cadence Design (CDNS) to Outperform from Market Perform following the stock's recent selloff and underperformance compared to peers Synopsys (SNPS) and Ansys (ANSS). He has raised his "Street-high" FY21 estimates based on his belief that the company should see initial revenue from its recent launch of two new products for the systems analysis market, Clarity and Celsius, the analyst noted. Diversification is key for Cadence given that the company, along with Synopsys, already have nearly 70% market share in the EDA software tools market, Mobley added in his upgrade note. He raised his price target on Cadence shares to $80, up from $70.
11/18/19
11/18/19
NO CHANGE

Ansys management to meet with Benchmark
Group Luncheon with CFO Shields and Investor Relations Arribas in New York on November 18 at 12:30 pm hosted by Benchmark.
AZN AstraZeneca
$48.21

0.295 (0.62%)

11/22/19
11/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Duke Energy (DUK) initiated with a Neutral at Mizuho. 2. Lancaster Colony (LANC) initiated with a Neutral at DA Davidson. 3. LendingTree (TREE) initiated with an Overweight at JPMorgan. 4. Zoom Video (ZM) initiated with a Buy at Guggenheim. 5. AstraZeneca (AZN) initiated with an Outperform at SVB Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/19
COWN
12/02/19
NO CHANGE
Target $55
COWN
Outperform
AstraZeneca price target raised to $55 from $48 at Cowen
Cowen analyst Steve Scala raised his price target on AstraZeneca to $55 from $48 as he believes its product momentum and high relative growth are not recognized. The analyst believes there is opportunity for upside as forecasts are below the company's guidance and its low relative exposure to the U.S. makes it less vulnerable to election rhetoric. Scala reiterated his Outperform rating on AstraZeneca shares.
11/22/19
LEER
11/22/19
INITIATION
Target $57
LEER
Outperform
AstraZeneca initiated with an Outperform at SVB Leerink
SVB Leerink analyst Andrew Berens initiated coverage of AstraZeneca with an Outperform rating and $57 price target.
11/15/19
GUGG
11/15/19
NO CHANGE
Target $228
GUGG
Buy
BeiGene price target raised to $228 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target for BeiGene (BGNE) to $228 from $205 saying FDA approval of Brukinsa over three months ahead of the action date provides additional validation of the company's strategy and ability to execute. He thinks Brukinsa's label in mantle cell lymphoma indicates a "potentially best-in-class" product profile with "nuanced differences" compared to AstraZeneca's (AZN) Calquence and "significantly better" than AbbVie's (ABBV) Imbruvica. The analyst maintains a Buy rating on BeiGene shares.
BASFY BASF
$0.00

(0.00%)

07/09/19
JPMS
07/09/19
DOWNGRADE
JPMS
Neutral
BASF downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chetan Udeshi downgraded BASF to Neutral from Overweight and lowered his price target for the shares to 59 euros from 72 euros following yesterday's profit earnings.
09/10/19
SBSH
09/10/19
DOWNGRADE
SBSH
Neutral
BASF downgraded to Neutral from Buy at Citi
Citi downgraded BASF to Neutral from Buy.
07/17/19
GSCO
07/17/19
DOWNGRADE
Target $31
GSCO
Sell
Trinseo downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Robert Koort said he believes investor expectations are muted ahead of Q2 earnings from the chemicals names. As proof, he noted that five negative pre-announcements - from LyondellBasell (LYB), Westlake Chemical (WLK), H.B. Fuller (FUL), Olin (OLN) and BASF (BASFY) - have been followed by a "modest" 1% average decline on the first full trading day following each announcement. In the preview note, he downgraded Trinseo (TSE) to Sell from Neutral, stating that he views styrene as the least favored commodity for cyclicals within his coverage. Koort expects styrene operating rates to decline 6 percentage points through 2022 as Chinese capacity additions outpace his "ambitious" demand growth estimate of 2.3%, he noted. Koort lowered his price target for Trinseo shares to $31.
07/09/19
HSBC
07/09/19
DOWNGRADE
HSBC
Hold
BASF downgraded to Hold from Buy at HSBC
HSBC analyst Sriharsha Pappu downgraded BASF to Hold from Buy with a reduced price target of 61 euros.
BAYRY Bayer
$0.00

(0.00%)

08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
10/21/19
PIPR
10/21/19
NO CHANGE
Target $100
PIPR
Overweight
Piper reiterates Overweight on Crispr Therapeutics with $100 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics (CRSP) with a $100 price target after the company announced the consolidation of the Casebia joint venture with Bayer (BAYRY). Casebia will now operate within Crispr to develop its hemophilia, ophthalmology and autoimmune programs, Tenthoff tells investors in a research note. The primary driver for shares remains first ever CTX001 data in beta thalassemia and sickle cell disease in December, says Tenthoff.
07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
DEO Diageo
$161.78

-0.285 (-0.18%)

10/24/19
MSCO
10/24/19
INITIATION
MSCO
Overweight
Diageo initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Valentina Sponza assumed coverage of Diageo with an Overweight rating and 3,500p price target.
09/10/19
BERN
09/10/19
UPGRADE
BERN
Market Perform
Diageo upgraded to Market Perform from Underperform at Bernstein
12/03/19
RBCM
12/03/19
UPGRADE
Target $3500
RBCM
Outperform
Diageo upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst James Jones upgraded Diageo to Outperform from Sector Perform with an increased price target of 3,500 GBp. The company's revenue growth is among the best in consumer staples, Jones tells investors in a research note.
09/10/19
BERN
09/10/19
UPGRADE
BERN
Market Perform
Diageo upgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst Trevor Stirling upgraded Diageo to Market Perform from Underperform on sector valuation. The analyst argues that the stable growth and highly cash-generative nature of European Beverages warrants a higher premium than was the case 10 years ago.
E Eni SpA
$30.22

0.415 (1.39%)

09/16/19
JPMS
09/16/19
NO CHANGE
JPMS
JPMorgan bullish on European oil stocks, sees demand 4% by 2040
Despite energy efficiency improvements in the West, global energy consumption is expected to continue to grow, led by Asia, JPMorgan analyst Christyan Malek tells investors in a research note. The analyst, who believes decarbonizing will be "far harder than current consensus assumes," estimates oil demand will be 4% higher than current levels by 2040, with demand growth peaking during 2035 through 2040. Amidst this backdrop, Malek has turned bullish on oil equities. The analyst's top pick is Royal Dutch Shell (RDS.A) and he reiterates an Overweight rating on BP (BP). Malek today upgraded Total (TOT) to Overweight from Neutral as he believes the company is best placed to reduce its own emissions intensity from core businesses and products and capture new sources of global energy demand growth. Malek also upgraded Equinor (EQNR) to Neutral from Underweight and following a period of restriction, moved to an Underweight from Neutral on Eni SpA (ENI) and Overweight rating on OMV AG (OMVKY).
09/04/19
FBCO
09/04/19
DOWNGRADE
FBCO
Neutral
Eni SpA downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Thomas Adolff downgraded Eni SpA to Neutral from Outperform with a price target of 18.10 euros.
09/16/19
JPMS
09/16/19
INITIATION
JPMS
Underweight
Eni SpA resumed with an Underweight at JPMorgan
JPMorgan analyst Christyan Malek resumed coverage of Eni SpA with an Underweight following a period of restriction.
09/16/19
BREN
09/16/19
DOWNGRADE
BREN
Hold
Eni SpA downgraded to Hold from Buy at Berenberg
Berenberg analyst Henry Tarr downgraded Eni SpA to Hold from Buy and lowered his price target for the shares to 15.50 euros from 18 euros.
FMS Fresenius Medical
$36.66

0.365 (1.01%)

02/21/19
RHCO
02/21/19
NO CHANGE
Target $48
RHCO
Buy
Fresenius Medical price target raised to $48 from $40 at SunTrust
SunTrust analyst David MacDonald raised his price target on Fresenius Medical to $48 and kept his Buy rating after its Q4 results yesterday, saying the quarter was "marked by solid organic trends, ongoing efficiency gains and strong cash flow." The analyst anticipates the company's 2019 to be a year of investment but sees the incremental spending driving more optimization and positioning Fresenius Medical for "attractive growth opportunities". MacDonald adds that he is positive on the company's pending acquisition of NxStage Medical (NXTM) given the market shift "towards the home".
10/23/19
REDB
10/23/19
DOWNGRADE
REDB
Neutral
Redburn downgrades Fresenius Medical to Neutral on growth concerns
Redburn analyst Ed Ridley-Day downgraded Fresenius Medical Care to Neutral from Buy and lowered his implied fair value estimate to 68 euros from 81 euros. Fresenius may not be able to achieve a return to high-single-digit earnings growth with pressure on margins likely to persist, Ridley-Day tells investors in a research note. He sees increasing risks around the company's U.S. dialysis business and limited potential recovery in Care Coordination.
10/23/19
REDB
10/23/19
DOWNGRADE
REDB
Neutral
Fresenius Medical downgraded to Neutral from Buy at Redburn
Redburn analyst Ed Ridley-Day downgraded Fresenius Medical Care to Neutral from Buy.
06/20/19
LEHM
06/20/19
UPGRADE
LEHM
Overweight
Fresenius Medical upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Hassan Al-Wakeel upgraded Fresenius Medical Care to Overweight from Equal Weight and raised his price target for the shares to 81.50 euros from 71 euros. After speaking with CEO Rice Powell and a deep-dive into U.S. dialysis market fundamentals, the analyst believes market concerns around the medium-term sustainability of growth are likely overdone. The analyst has started to see some improvements in the business and believes expectations are now achievable. He now sees a "compelling" risk/reward over the medium term for shares of Fresenius Medical.
GLPG Galapagos
$205.53

3.65 (1.81%)

10/29/19
CANT
10/29/19
NO CHANGE
Target $187
CANT
Overweight
Galapagos outlook unchanged after MOR106 discontinuation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle says she still expects a "strong" 2020 from Galapagos following the announcement that clinical development of MOR106 in atopic dermatitis has been stopped for futility. The analyst lowered her price target for the shares to $187 from $188 and reiterates an Overweight rating on the name. She thinks there was "limited investor credit baked in" for the MOR106 program and that Galapagos had relatively limited economics. Many clinical catalysts in 2020 are underappreciated for Galapagos, Merle tells investors in a research note.
09/10/19
MSCO
09/10/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos (GLPG) with an Overweight rating and $200 price target. The analyst believes Galapagos is well positioned for success following the transaction with Gilead (GILD). He believes Gilead offers a "strong partner" to drive the company's "broad" pipeline while building commercial operations in Europe. Filgotinib will drive near-term upside in Galapagos shares while its greater than $5B cash position provides downside protection, Harrison tells investors in a research note.
12/02/19
BOFA
12/02/19
INITIATION
Target $199
BOFA
Neutral
Galapagos initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated coverage of Galapagos with a Neutral rating and $199 price target. The analyst is positive on the company's lead filgotinib asset targeting rheumatoid arthritis and expects the drug to gain FDA approval next year, but he also sees "limited catalysts" over the near term.
11/15/19
RBCM
11/15/19
NO CHANGE
Target $158
RBCM
Sector Perform
Galapagos price target raised to $158 from $152 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Galapagos (GLPG) to $158 after the company's R&D day, where the management revealed its "expansive plans for bringing new discovery techniques, treatment modalities, preclinical assets, and targeted indications online" by using the cash from its recent Gilead (GILD) deal. While these "aspirations" will take time to mature, the analyst says the plans are "impressive". Abrahams still keeps his Sector Perform rating on Galapagos shares, noting that its nearer term positives of filgotinib commercialization in RA and potential expansion into IB look priced in.
GSK GlaxoSmithKline
$45.07

0.41 (0.92%)

11/21/19
UBSW
11/21/19
UPGRADE
UBSW
Buy
GlaxoSmithKline upgraded to Buy from Neutral at UBS
UBS upgraded GlaxoSmithKline to Buy from Neutral with a price target of 1900 pence, up from 1610 pence.
12/03/19
MSCO
12/03/19
NO CHANGE
Target $100
MSCO
Equal Weight
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
Morgan Stanley analyst Matthew Harrison said he sees a high probability, or 75% odds, that Bluebird Bio (BLUE) shares will trade higher following the report of topline results from its KarMMa study of bb2121 as a fourth line or later therapy for the treatment of relapsed/refractory multiple myeloma, which are due by year-end. He said investors are focused on the median progression free survival delivered by the therapy as a gauge of its commercial viability versus other anti-BCMA CAR-T therapies in development at GlaxoSmithKline (GSK) and Bristol-Myers (BMY) in partnership with Regeneron (REGN). In a scenario where median PFS is greater than or equal to 11.5 months and overall response rate is greater than or equal to 85%, Harrison sees Bluebird shares having 20%-30% or more upside. If the median PFS is equal to or less than 9 months and ORR is below 80%, he thinks bb2121 would likely still be approvable, but sees shares down 10%-20%. In what he views as the most likely scenario - with mPFS of about 10 months and ORR of about 80% - Harrison sees 10%-20% upside in Bluebird shares. He keeps an Equal Weight rating and $100 price target on the stock.
11/21/19
11/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Kate McShane saying the retailer's Q3 results represented a positive step in rebuilding investor confidence around its execution capabilities and transformation strategy. 2. NorthWestern (NWE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jonathan Reeder saying the stock's price-to-earnings "looks too steep" at current valuation levels. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS. 4. Kimco Realty (KIM) upgraded to Outperform from Sector Perform at Scotiabank. 5. Kulicke & Soffa (KLIC) upgraded to Buy from Neutral at DA Davidson analyst Thomas Diffely saying the company is now past its "trough quarter" and expects its "upcoming cyclical drivers" to generate revenue growth as "pockets of strength in the wirebonding market" serve as initial indicators of a broader industry recovery. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/19
LEER
12/02/19
INITIATION
Target $53
LEER
Outperform
GlaxoSmithKline initiated with an Outperform at SVB Leerink
SVB Leerink analyst Geoffrey Porges initiated coverage of GlaxoSmithKline with an Outperform rating and $53 price target.
JMPLY Johnson Matthey
$0.00

(0.00%)

09/17/19
LEHM
09/17/19
DOWNGRADE
LEHM
Equal Weight
Johnson Matthey downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Alex Stewart downgraded Johnson Matthey to Equal Weight from Overweight with a price target of 37.90 pounds, down from 40.80 pounds.
11/28/19
JPMS
11/28/19
DOWNGRADE
Target $2850
JPMS
Underweight
Johnson Matthey downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Chetan Udeshi downgraded Johnson Matthey to Underweight from Neutral with a 2,850 GBp price target. The analyst sees increasing growth headwinds in the company's engine-catalysts business.
MOR MorphoSys
$32.08

0.72 (2.30%)

11/18/19
PIPR
11/18/19
NO CHANGE
Target $42
PIPR
Overweight
MorphoSys B-MIND futility analysis success de-risks stock, says Piper Jaffray
Piper Jaffray analyst Danielle Brill said news that MOR208 successfully passed the B-MIND trial futility analysis is "a positive clearing event for investors" that de-risks the stock, even though enrollment will be expanded from 300 to 450 patients and it is unclear how strong the efficacy signal was in the overall population. She continues to expect FDA and EMA approval for MOR208 based on L-MIND data by mid-2020 and keeps an Overweight rating on MorphoSys shares.
11/20/19
GUGG
11/20/19
INITIATION
GUGG
Buy
Guggenheim starts MorphoSys with Buy rating, EUR 126 price target
Guggenheim analyst Etzer Darout initiated coverage of MorphoSys with a Buy rating and EUR 126 price target. The company has an established antibody platform that has generated a number of proprietary and partnered discovery assets that have advanced to late-stage clinical pipelines, Darout tells investors in a research note. The analyst sees a positive risk/reward for tafasitamab with a potential approval in relapsed/refractory diffuse large B-cell lymphoma in mid-2020.
11/19/19
DBAB
11/19/19
NO CHANGE
DBAB
Buy
MorphoSys news a best case scenario, says Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis views MorphoSys announcement that B-MIND, the Phase III study of tafasitamab/bendamustine vesus rituximab/bendamustine, successfully passed its interim analysis for futility as a "best case scenario." Assuming accelerated approval for tafasitamab, the analyst expects B-MIND to serve as the confirmatory study when it reads out in a few years. The analyst reiterates MorphoSys as his top pick with a Buy rating and EUR 129 price target.
11/19/19
GUGG
11/19/19
INITIATION
GUGG
Buy
MorphoSys initiated with a Buy at Guggenheim
Guggenheim analyst Etzer Darout initiated coverage of MorphoSys with a Buy rating and EUR126 price target.
NVO Novo Nordisk
$57.37

0.835 (1.48%)

11/19/19
HCWC
11/19/19
NO CHANGE
Target $30
HCWC
Buy
Dicerna price target raised to $30 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Dicerna Pharmaceuticals (DRNA) to $30 from $22 after the company after announced a new strategic alliance with Novo Nordisk (NVO). The analyst sees "favorable deal terms embedded with optionality." He continues to view Dicerna as a "core, pure-play holding" in the greater nucleic acid therapy space and reiterates a Buy rating on the shares.
11/22/19
PART
11/22/19
DOWNGRADE
PART
Hold
Novo Nordisk downgraded to Hold from Buy at Pareto
Pareto analyst Johan Unnerus downgraded Novo Nordisk to Hold from Buy with a price target of 385 kroner.
11/19/19
RHCO
11/19/19
NO CHANGE
Target $28
RHCO
Buy
Dicerna price target raised to $28 from $24 at SunTrust
SunTrust analyst Robyn Karnauskas raised her price target on Dicerna (DRNA) to $28 and kept her Buy rating, saying the company's collaboration with Novo Nordisk (NVO) on liver-related cardiometabolic disease candidates demonstrate its ability to participate in larger deals with upside optionality. The analyst believes that Dicerna can become a "larger platform play" over the long term, comparable to Ionis Pharma (IONS) and Alnylam (ALNY).
11/19/19
LEER
11/19/19
NO CHANGE
Target $30
LEER
Outperform
Dicerna price target raised to $30 from $26 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna (DRNA) to $30 from $26 and maintained an Outperform rating after the company announced a collaboration with Novo Nordisk (NVO) to develop candidates for liver-related cardiometabolic diseases. In a research note to investors, Foroohar says that while Dicerna's stock has traded up about 30% since the announcement of a partnership with Roche (RHHBY), it remains undervalued.
NVS Novartis
$91.56

0.515 (0.57%)

11/25/19
BARD
11/25/19
DOWNGRADE
Target $85
BARD
Neutral
The Medicines Co. downgraded to Neutral from Outperform at Baird
Baird analyst Madhu Kumar downgraded The Medicines Co. (MDCO) to Neutral from Outperform with an $85 price target after the company reached an agreement to be acquired by Novartis (NVS).
11/25/19
OPCO
11/25/19
DOWNGRADE
Target $85
OPCO
Perform
The Medicines Co. downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded The Medicines Co. (MDCO) to Outperform from Perform with a price target of $85, up from $68, after it agreed to be acquired by Novartis (NVS) for $9.7B. After months of impressive data presentations for inclisiran and media reports of alleged negotiations with potential acquirers, Olson says that this this deal announcement brings welcomed news to The Medicines Co. investors who were patient enough to "weather an exciting ride."
12/04/19
BOFA
12/04/19
NO CHANGE
Target $104
BOFA
Buy
BofA/Merrill recommends investors buy Novartis on new product growth
BofA/Merrill analyst Graham Parry keeps his Buy rating and CHF104 price target on Novartis in spite of lowering his FY20 EPS view to $5.64 from $5.92 to reflect the dilution from its Medicines Co acquisition and expected completion of the US generics divestment to Aurobindo. The analyst cites the company's expected new launches and forecasts "premium growth" from its new products, saying its sales are set to rise about 7% in 2019-2022 thanks to its "16 key growth products and Pharma margin expansion" to 37.1% from 33.3% this year.
11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform after Medicines Company takeover at Baird
As previously reported, Baird analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals (ARWR) to Outperform from Neutral with a price target of $70, up from $39, after Medicines Company (MDCO) announced a definitive agreement to be acquired by Novartis (NVS). That deal forces Kumar to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease, the analyst tells investors. Given the early positive efficacy for Arrowhead's ANGPTL3 and APOC3 RNAi drugs presented at the American Heart Association meeting, Kumar believes these programs have "the chance to dominate the ANGPTL3 and APOC3 landscapes," though cautions both are "quite early."
SOLVY Solvay
$0.00

(0.00%)

11/12/19
BREN
11/12/19
UPGRADE
BREN
Buy
Solvay upgraded to Buy from Hold at Berenberg
Berenberg analyst Sebastian Bray upgraded Solvay to Buy from Hold with a price target of 120 euros, up from 120 euros. The analyst says Solvay has become the "most undervalued large-cap chemicals name in Europe." Further, he believes earnings expectations for 2020 are now reasonable.
RHHBY Roche
$0.00

(0.00%)

11/01/19
HCWC
11/01/19
NO CHANGE
Target $22
HCWC
Buy
Dicerna HBV deal earlier, on better terms than expected, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirmed his Buy rating on Dicerna Pharmaceuticals (DRNA) shares after the companpy announced a collaboration and licensing agreement with Roche (RHHBY) for the worldwide development and commercialization the company's lead asset for the treatment of hepatitis B virus, or HBV. While he has long anticipated "a large HBV deal," the collaboration with Roche is earlier, and with better economics, than Arce had expected, the analyst tells investors. He maintains a $22 price target on Dicerna shares.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
11/01/19
LEER
11/01/19
NO CHANGE
Target $26
LEER
Outperform
Dicerna price target raised to $26 from $22 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna Pharmaceuticals (DRNA) to $26 from $22 saying the terms for the company's partnership with Roche (RHHBY) to develop and commercialize DCR-HBVS are "quite favorable." Dicerna will receive a $200M upfront payment, up to $1.47B in potential milestones, and up to mid-teens royalties on future sales. The transaction is "meaningfully validating" for Dicerna's strategy for large population indications, Foroohar tells investors in a research note. With shares trading at an implied enterprise value "materially below" the pre-deal value, investors should begin to appreciate the scope of the potential partnership opportunities, says the analyst. He keeps an Outperform rating on Dicerna.
RYCEY Rolls-Royce
$0.00

(0.00%)

11/11/19
SOCG
11/11/19
DOWNGRADE
SOCG
Hold
Rolls-Royce downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Zafar Khan downgraded Rolls-Royce to Hold from Buy with a price target of 825 pence.
10/18/19
REDB
10/18/19
DOWNGRADE
REDB
Neutral
Rolls-Royce downgraded to Neutral from Buy at Redburn
Redburn analyst Jeremy Bragg downgraded Rolls-Royce to Neutral from Buy.
UL Unilever
$59.52

0.31 (0.52%)

09/01/19
GSCO
09/01/19
UPGRADE
GSCO
Buy
Unilever upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst John Ennis upgarded Unilever to Buy from Neutral and raised his price target for the shares to 62 euros from 54 euros. The analyst expects the company's growth to pick up in 2020 as India, Brazil and Indonesia start to improve. Further, after underperforming year-to-date, Unilever shares now trade at a 6% price-to-earnings ratio discount on 2020 estimates relative to peers, Ennis tells investors in a research note.
09/18/19
MSCO
09/18/19
NO CHANGE
MSCO
EU Household & Personal Care sector downgraded to In-Line at Morgan Stanley
Morgan Stanley analyst Richard Taylor downgraded the European Household & Personal Care, or HPC, sector to In-Line from Attractive to reflect a fading pricing environment in the second half of 2019 and competitive pressures that he sees increasing. Procter & Gamble (PG), after nearly 10 years of losing share to the big players in Europe, is now growing fast and gaining share under new management, Taylor tells investors. His least preferred name in the group is Henkel (HENKY), on which he has an Underweight rating. Other European HPC companies include Unilever (UN, UL), Reckitt Benckiser (RBGLY) and L'Oreal (LRLCY).
12/02/19
LIBM
12/02/19
UPGRADE
Target $5100
LIBM
Buy
Unilever upgraded to Buy from Hold at Liberum
Liberum analyst Nico Von Stackelberg upgraded Unilever to Buy from Hold with a 5,100 GBp price target. Unilever's acquisitions and divestitures can transition it to a mid-single-digit growth company, Von Stackelberg tells investors in a research note. Further, its current pace of annual cost savings creates room to reinvest in brands and exceed 20% operating profit margins, adds the analyst.
10/11/19
REDB
10/11/19
DOWNGRADE
REDB
Sell
Unilever downgraded to Sell from Neutral at Redburn
Redburn analyst Chris Pitcher downgraded Unilever to Sell from Neutral.
NVZMY Novozymes
$0.00

(0.00%)

09/30/19
JPMS
09/30/19
DOWNGRADE
JPMS
Underweight
Novozymes downgraded to Underweight from Neutral at JPMorgan
Before the open, JPMorgan analyst Jeffrey Zekauskas downgraded Novozymes to Underweight from Neutral and lowered his price target for the shares to 270 kroner from 275 kroner. Zekauskas said he believes lower oil prices could lead to "poor" organic growth in 2019, and lead to 2020 being below the company's longer-term annual organic growth rate of more than 5%.
08/19/19
JPMS
08/19/19
UPGRADE
JPMS
Neutral
Novozymes upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Novozymes to Neutral from Underweight with an unchanged price target of 275 kroner, stating that he thinks the shares are trading closer to fair value at this time.
11/20/19
SBSH
11/20/19
UPGRADE
SBSH
Buy
Novozymes upgraded to Buy from Neutral at Citi
Citi analyst Charles Greig upgraded Novozymes to Buy from Neutral with a price target of DKK 360. The analyst sees strong new sources of revenue growth and believes the company will be able to meet its updated targets.
03/26/19
JPMS
03/26/19
DOWNGRADE
JPMS
Underweight
Novozymes downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Novozymes to Underweight from Neutral with a price target of 275 kroner.

TODAY'S FREE FLY STORIES

WFT

Weatherford

$0.00

(0.00%)

18:49
12/13/19
12/13
18:49
12/13/19
18:49
Hot Stocks
Weatherford completes financial restructuring, emerges from Chapter 11 »

Weatherford announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$57.71

-0.81 (-1.38%)

18:40
12/13/19
12/13
18:40
12/13/19
18:40
Hot Stocks
Centene CEO: Our big markets are growing, we're gaining share »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

18:29
12/13/19
12/13
18:29
12/13/19
18:29
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

PLAN

Anaplan

$51.80

1.44 (2.86%)

18:23
12/13/19
12/13
18:23
12/13/19
18:23
Hot Stocks
Anaplan CEO: Digitization has really started to accelerate »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

18:08
12/13/19
12/13
18:08
12/13/19
18:08
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HLIT

Harmonic

$7.94

-0.25 (-3.05%)

17:47
12/13/19
12/13
17:47
12/13/19
17:47
Hot Stocks
Harmonic CFO sells 28K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

(0.00%)

17:36
12/13/19
12/13
17:36
12/13/19
17:36
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma up 9.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:33
12/13/19
12/13
17:33
12/13/19
17:33
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin rises 1.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

THMO

ThermoGenesis

$2.88

(0.00%)

17:31
12/13/19
12/13
17:31
12/13/19
17:31
Syndicate
Breaking Syndicate news story on ThermoGenesis »

ThermoGenesis files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:30
12/13/19
12/13
17:30
12/13/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Amarin 

Amarin trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

QTNT

Quotient

$8.60

-0.165 (-1.88%)

17:28
12/13/19
12/13
17:28
12/13/19
17:28
Syndicate
Breaking Syndicate news story on Quotient »

Quotient files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

, GVA

Granite Construction

$26.21

-1.335 (-4.85%)

17:27
12/13/19
12/13
17:27
12/13/19
17:27
Hot Stocks
Breaking Hot Stocks news story on Arrowhead, Granite Construction »

Arrowhead to replace…

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

, SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

17:25
12/13/19
12/13
17:25
12/13/19
17:25
Hot Stocks
Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 »

Oasis Petroleum (OAS) and…

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:24
12/13/19
12/13
17:24
12/13/19
17:24
Hot Stocks
Amarin raises guidance after FDA approves Vascepa »

Amarin (AMRN) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

, LEA

Lear

$129.43

-0.84 (-0.64%)

17:22
12/13/19
12/13
17:22
12/13/19
17:22
Hot Stocks
Grand Canyon, Lear to replace Oasis, Southwestern in S&P 400 at open on 12/23 »

Grand Canyon Education…

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

RTN

Raytheon

$217.31

-0.93 (-0.43%)

17:20
12/13/19
12/13
17:20
12/13/19
17:20
Hot Stocks
Raytheon awarded $123.53M Navy contract modification »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

17:19
12/13/19
12/13
17:19
12/13/19
17:19
Hot Stocks
Live Nation, Zebra Technologies, Steris to move to S&P 500 at open on 12/23 »

Live Nation (LYV), Zebra…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BAESY

BAE Systems

$0.00

(0.00%)

17:15
12/13/19
12/13
17:15
12/13/19
17:15
Hot Stocks
BAE Systems awarded $249.15M Army contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$146.32

-0.14 (-0.10%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Hot Stocks
West Pharmaceutical announces 848K share repurchase authorization »

On December 10, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Earnings
Amarin sees FY20 revenue $650M-$700M, consensus $654.55M »

With respect to 2020,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

IBIO

iBio

$0.22

-0.0179 (-7.43%)

17:01
12/13/19
12/13
17:01
12/13/19
17:01
Hot Stocks
iBio receives NYSE noncompliance notice »

iBio, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLT

Applied Therapeutics

$21.23

0.29 (1.38%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Syndicate
Breaking Syndicate news story on Applied Therapeutics »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Earnings
Amarin raises FY19 revenue view to $410M-$425M from $380M-$420M 

FY19 consensus $410.25M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

BIO

Bio-Rad

$354.69

-8.005 (-2.21%)

16:56
12/13/19
12/13
16:56
12/13/19
16:56
Hot Stocks
Bio-Rad progressing from ransomware attack recovery detected on Dec 5th »

Bio-Rad Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:50
12/13/19
12/13
16:50
12/13/19
16:50
Hot Stocks
Amarin confirms FDA approval of Vascepa »

Amarin announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.